Vancomycin resistant Staphylococcus aureus infections: A review of case updating and clinical features

Yanguang Cong; Sijin Yang; Xiancai Rao

doi:10.1016/j.jare.2019.10.005

Vancomycin resistant Staphylococcus aureus infections: A review of case updating and clinical features

J Adv Res. 2019 Oct 12:21:169-176. doi: 10.1016/j.jare.2019.10.005. eCollection 2020 Jan.

Authors

Yanguang Cong¹, Sijin Yang², Xiancai Rao³

Affiliations

¹ Department of Clinical Laboratory, Traditional Medicine Hospital Affiliated to Southwest Medical University, Luzhou, Sichuan 646000, China.
² Department of Cardiovascular Disease, Traditional Medicine Hospital Affiliated to Southwest Medical University, Luzhou, Sichuan 646000, China.
³ Department of Microbiology, College of Basic Medical Sciences, Army Medical University (Third Military Medical University), Chongqing 400038, China.

Abstract

The infection caused by methicillin-resistant Staphylococcus aureus (MRSA) is a global threat to public health. Vancomycin remains one of the first-line drugs for the treatment of MRSA infections. However, S. aureus isolates with complete resistance to vancomycin have emerged in recent years. Vancomycin-resistant S. aureus (VRSA) is mediated by a vanA gene cluster, which is transferred from vancomycin-resistant enterococcus. Since the first VRSA isolate was recovered from Michigan, USA in 2002, 52 VRSA strains have been isolated worldwide. In this paper, we review the latest progresses in VRSA, highlighting its resistance mechanism, characteristics of VRSA infections, as well as clinical treatments.

Keywords: Treatment; Vancomycin; Vancomycin-resistant Staphylococcus aureus; vanA cluster.

Publication types

Review